Table 5 Diseases and number of subjects treated with different anti-angiogenic drugs
Anti-VEGF molecules | Avastin | Lucentis | Accentrix | Eylea | Razumab | Anti-VEGF (not specified) |
|---|---|---|---|---|---|---|
Total number of subjects | 3706 | 942 | 860 | 35 | 310 | 279 |
Diseases wise distribution | ||||||
Wet AMD | 60 | 17 | 23 | 3 | 7 | 5 |
AMD | 102 | 36 | 38 | 8 | 17 | 10 |
Diabetic retinopathy | 1272 | 256 | 190 | _ | 65 | 75 |
Retinal vein occlusion | 496 | 122 | 119 | 4 | 28 | 26 |
Myopic CNMV | 4 | 1 | _ | _ | _ | _ |
Pathological myopia | 5 | 3 | 1 | _ | 1 | 1 |
Neovascular glaucoma | 199 | 37 | 27 | 1 | 10 | 12 |
Retinopathy of prematurity | 2 | _ | _ | _ | _ | _ |
Retinal vascular disorder | 579 | 174 | 65 | 10 | 18 | 21 |
Retinal vasculitis | 20 | 3 | 2 | _ | _ | 1 |
Chorioretinopathy | 20 | 7 | 4 | 1 | 1 | 3 |